척추 바이오로직스 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 수술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Spine Biologics Market Size, Share & Trends Analysis Report By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix), By Surgery, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,572,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,013,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,895,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

척추 바이오로직스 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 척추 바이오로직스 세계 시장 규모는 2030년까지 43억 8,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 4.9%의 CAGR로 확대될 것으로 예상됩니다.

이 시장을 주도하는 것은 주로 척추 손상 발생률의 증가입니다. 척추 변형의 유병률은 선진국과 저개발국 모두에서 증가하는 추세이며, 그 결과 수술 건수가 증가하고 있습니다. 이는 척추 바이오로직스 시장에 긍정적인 영향을 미치고 있습니다.

이와는 별도로, 척추 고정 수술에서 생물학적 제제의 많은 장점, 예를 들어 수술 후 시간을 최소화하고 세포 증식을 활성화하는 능력에 대한 인식이 높아짐에 따라 시장을 촉진하고 있습니다. 척추 변형에 대한 치료 옵션으로 생체 재료와 뼈 이식 대체물이 점점 더 많이 사용되고 있습니다. 척추 질환을 앓고 있는 노인 인구의 비율이 증가하고 치료법으로 이러한 제품을 채택하는 비율이 증가함에 따라 예측 기간 동안 척추 바이오로직스 시장이 확대될 것으로 예상됩니다.

노년층은 척추 전방전위증과 디스크 퇴행성 질환에 걸리기 쉽습니다. 이와 함께 교통사고와 스포츠 외상으로 인한 외상 사례의 증가는 척추 바이오로직스에 대한 수요를 증가시키고 있으며, 2018년에 발간된 최소침습 수술(MIS) 오픈 액세스 저널에 따르면 최소침습 기술은 다양한 척추 병리 치료에 채택되고 있습니다. 미국에서는 매년 약 40만 건의 척추 고정술이 시행되고 있으며, 척추 외상, 퇴행성 질환, 종양 및 구조적 이상에 대해 가장 일반적으로 시행되고 확립된 치료법 중 하나로 밝혀졌습니다.

척추 바이오로직스 시장 보고서 하이라이트

• 척추 이식 분야는 2024년 세계 매출의 58.7%를 차지하며 시장을 장악했습니다. 이러한 우위는 동종 이식편 사용에 따른 많은 이점에 기인합니다.
• 병원 부문이 2024년 시장을 장악했습니다. 이 부문의 주요 요인은 이러한 시설에서 수행되는 척추 고정술의 수가 증가하고 있기 때문입니다.
• 북미가 2024년 48.2%의 점유율로 시장을 주도했습니다. 이 시장의 성장은 안정적인 경제 성장, 최소침습 수술의 채택 증가, 추간판 관련 문제, 척추관 협착증, 척추 전방 전위증과 같은 척추 질환의 유병률 증가에 기인합니다.
• 아시아태평양은 환자 수가 많고 환자와 외과의사들 사이에서 생물학적 제제의 이점에 대한 인식이 높아짐에 따라 시장이 빠르게 성장할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 척추 바이오로직스 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 척추 바이오로직스 시장 : 제품 비즈니스 분석

• 제품 시장 점유율, 2024년 및 2030년
• 제품 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 제품별, 2018-2030년
• 척추 동종이식
• 골이식 대체품
• 세포 기반 매트릭스

제5장 척추 바이오로직스 시장 : 수술 비즈니스 분석

• 수술 시장 점유율, 2024년과 2030년
• 수술 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 수술별, 2018-2030년
• 경추 전방 추간판절제술 및 고정술(ACDF)
• 경추간공 요추추체간 고정술(TLIF)
• 요추 후방추체간 고정술(PLIF)
• 요추 전방 고정술(ALIF)
• 측방 요추추체간 고정술(LLIF)

제6장 척추 바이오로직스 시장 : 최종 용도 비즈니스 분석

• 최종 용도 시장 점유율, 2024년 및 2030년
• 최종 용도 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 최종 용도별, 2018-2030년
• 병원
• 외래 시설

제7장 척추 바이오로직스 시장 : 제품별 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 척추 바이오로직스 시장 : 수술별 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 척추 바이오로직스 시장 : 최종 용도별 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제10장 경쟁 상황

• 진출 기업 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • Stryker
  • NuVasive, Inc.
  • Orthofix
  • DePuy Synthes(Johnson & Johnson)
  • Exactech, Inc.
  • Zimmer Biomet

ksm

영문 목차

영문목차

Spine Biologics Market Growth & Trends:

The global spine biologics market size is estimated to reach USD 4.38 billion by 2030, expanding at a CAGR of 4.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing incidence of spinal injuries. Prevalence of spinal deformities has been on a rise in developed and underdeveloped countries and this has resulted in an increase in the number of surgeries being carried. This has had a positive impact on the market for spine biologics.

Apart from this, growing awareness about numerous advantages of biologics in spine fusion surgeries, such as minimal postoperative time and ability to activate cellular growth, has also propelled the market. Biomaterials and bone graft substitutes are being adopted as the choice of treatment for spinal deformities. Increasing percentage of the elderly population suffering from spinal disorders and rising adoption of these products as a treatment method is anticipated to boost the market for spine biologics over the forecast period.

The geriatric population is more prone to spondylolisthesis and degeneration of disc. This, coupled with increasing number of trauma cases due to road accidents and sports injuries, is driving demand for spine biologics. According to the Open Access Journal for Minimally Invasive Surgery (MIS) published in 2018, minimally invasive techniques are being adopted for the treatment of a wide range of spine pathologies. Approximately 400,000 cases are performed in the U.S. annually and spine fusion has turned out to be one of the most commonly performed and well-established treatment options for spine trauma, degenerative disorders, tumors, and structural abnormalities.

Spine Biologics Market Report Highlights:

• The spinal allografts segment dominated the market and accounted for 58.7% of the global revenue in 2024. This dominance can be attributed to the numerous benefits associated with the usage of allografts.
• The hospital segment dominated the market in 2024. The segment is primarily driven by an increased number of spine fusion surgeries performed in these facilities.
• North America dominated the market and accounted for a 48.2% share in 2024. The growth of the market can be attributed to stable economic growth, increased adoption of minimally invasive surgeries, and rising prevalence of spine disorders such as disc-related issues, spinal stenosis, and spondylolisthesis.
• Asia Pacific is anticipated to witness the fastest growth in the market due to the presence of a large patient pool and growing awareness among patients and surgeons about the advantages of biologics.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Surgery
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Spine Biologics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Spine Biologics Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
• 4.4. Spinal Allografts
  • 4.4.1. Spinal Allografts Market, 2018 - 2030 (USD Billion)
    • 4.4.1.1. Machined Bones Allograft Market, 2018 - 2030 (USD Billion)
    • 4.4.1.2. Demineralized Bone Matrix Market, 2018 - 2030 (USD Billion)
• 4.5. Bone Graft Substitutes
  • 4.5.1. Bone Graft Substitutes Market, 2018 - 2030 (USD Billion)
    • 4.5.1.1. Bone Morphogenetic Proteins Market, 2018 - 2030 (USD Billion)
    • 4.5.1.2. Synthetic Bone Grafts Market, 2018 - 2030 (USD Billion)
• 4.6. Cell-based Matrix
  • 4.6.1. Cell-based Matrix Market, 2018 - 2030 (USD Billion)

Chapter 5. Spine Biologics Market: Surgery Business Analysis

• 5.1. Surgery Market Share, 2024 & 2030
• 5.2. Surgery Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Surgery, 2018 to 2030 (USD Billion)
• 5.4. Anterior Cervical Discectomy and Fusion (ACDF)
  • 5.4.1. Anterior Cervical Discectomy and Fusion (ACDF) Market, 2018 - 2030 (USD Billion)
• 5.5. Transforaminal Lumbar Interbody Fusion (TLIF)
  • 5.5.1. Transforaminal Lumbar Interbody Fusion (TLIF) Market, 2018 - 2030 (USD Billion)
• 5.6. Posterior Lumbar Interbody Fusion (PLIF)
  • 5.6.1. Posterior Lumbar Interbody Fusion (PLIF) Market, 2018 - 2030 (USD Billion)
• 5.7. Anterior Lumbar Interbody Fusion (ALIF)
  • 5.7.1. Anterior Lumbar Interbody Fusion (ALIF) Market, 2018 - 2030 (USD Billion)
• 5.8. Lateral Lumbar Interbody Fusion (LLIF)
  • 5.8.1. Lateral Lumbar Interbody Fusion (LLIF) Market, 2018 - 2030 (USD Billion)

Chapter 6. Spine Biologics Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
• 6.4. Hospitals
  • 6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
• 6.5. Outpatient Facilities
  • 6.5.1. Outpatient Facilities Market, 2018 - 2030 (USD Billion)

Chapter 7. Spine Biologics Market: Regional Estimates & Trend Analysis by Product

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Europe
  • 7.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.8. MEA
  • 7.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Spine Biologics Market: Regional Estimates & Trend Analysis by Surgery

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.5. Europe
  • 8.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.7. Latin America
  • 8.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.8. MEA
  • 8.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Spine Biologics Market: Regional Estimates & Trend Analysis by End Use

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Framework
    • 9.4.2.3. Competitive Insights
    • 9.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Framework
    • 9.4.3.3. Competitive Insights
    • 9.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Framework
    • 9.4.4.3. Competitive Insights
    • 9.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.5. Europe
  • 9.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Framework
    • 9.5.2.3. Competitive Insights
    • 9.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Framework
    • 9.5.3.3. Competitive Insights
    • 9.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Regulatory Framework
    • 9.5.4.3. Competitive Insights
    • 9.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Regulatory Framework
    • 9.5.5.3. Competitive Insights
    • 9.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Regulatory Framework
    • 9.5.6.3. Competitive Insights
    • 9.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.7. Norway
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Regulatory Framework
    • 9.5.7.3. Competitive Insights
    • 9.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.8. Denmark
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Regulatory Framework
    • 9.5.8.3. Competitive Insights
    • 9.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.9. Sweden
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Regulatory Framework
    • 9.5.9.3. Competitive Insights
    • 9.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Framework
    • 9.6.2.3. Competitive Insights
    • 9.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Regulatory Framework
    • 9.6.3.3. Competitive Insights
    • 9.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Regulatory Framework
    • 9.6.4.3. Competitive Insights
    • 9.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.5. South Korea
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Regulatory Framework
    • 9.6.5.3. Competitive Insights
    • 9.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.6. Australia
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Regulatory Framework
    • 9.6.6.3. Competitive Insights
    • 9.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Regulatory Framework
    • 9.6.7.3. Competitive Insights
    • 9.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.7. Latin America
  • 9.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Regulatory Framework
    • 9.7.2.3. Competitive Insights
    • 9.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Regulatory Framework
    • 9.7.3.3. Competitive Insights
    • 9.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.8. MEA
  • 9.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Regulatory Framework
    • 9.8.2.3. Competitive Insights
    • 9.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Regulatory Framework
    • 9.8.3.3. Competitive Insights
    • 9.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Regulatory Framework
    • 9.8.4.3. Competitive Insights
    • 9.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Regulatory Framework
    • 9.8.5.3. Competitive Insights
    • 9.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Stryker
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. NuVasive, Inc.
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Orthofix
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. DePuy Synthes (Johnson & Johnson)
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Exactech, Inc.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Zimmer Biomet
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives

관련자료